By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
LATEST POSTS
- 1
6 Agreeable Earphones To Wear - 2This country music star spent years hiding his sexuality. Coming out — and beating addiction — has made his soul feel '20 pounds lighter.'
- 3Unsold Rams May Be Less expensive Than You Suspect
- 4The 1 question we have to ask ourselves about the Taylor Frankie Paul 'Bachelorette' scandal
- 5We may have less control over how long we live than previously thought
- Mountain Trekking on a Tight spending plan: Tracking down the Right Bicycle
- Thousands of Walgreens nasal spray bottles recalled. See which ones.
- Empathy and reasoning aren’t rivals – new research shows they work together to drive people to help more
- Luigi Mangione‘s lawyers say Bondi’s death penalty decision was tainted by conflict of interest
- Interpreter Starts Sobbing as 11-Year-Old Testifies About Last Time He Saw His Mom Before She Was Killed in Missile Strike
- Step by step instructions to Deal with Your Time While Chasing after an Internet based Degree
- Iran war triggering Easter staycation boom
- Inn The executives: A Remunerating Profession Decision for Energetic People
- 5 Language Learning Applications
